Kinfemichael Gedif, PhD

Novartis Pharmaceuticals Corporation, Fort Worth, TX, USA

Disclosure(s): Novartis Pharmaceuticals Corporation: Employee

Poster(s):

• 1130 - Ensovibep antiviral activity in ambulatory patients with COVID-19 is independent of baseline anti-SARS-CoV-2 antibodies and exhibits minimal selective pressure – Results from the placebo-controlled EMPATHY trial
  Friday, October 21, 2022

  12:15 PM – 1:30 PM US ET